Showing posts with label SkyCell. Show all posts
Showing posts with label SkyCell. Show all posts

Sunday, 14 November 2021

SkyCell and Japan Airlines partner to support the growing Japanese pharmaceutical shipment market

 SkyCell, the manufacturer of innovative hybrid pharmaceutical containers, has partnered with Japan Airlines Cargo (JAL Cargo), to meet the country's growing needs for vaccine and pharmaceutical transportation in a safe, secure, and sustainable way.

SkyCell is committed to working with JAL Cargo to offer a tailor-made solution that meets the airline's growing business needs across vaccine and pharmaceutical shipments. This partnership will also see SkyCell further strengthen its presence in Japan and continue to support the temperature-sensitive pharmaceutical market with its high-quality hybrid containers that have been industry accredited to have near-zero spoilage rates.

SkyCell’s GDP compliant hybrid containers - which maintain internal temperature stability across the pharmaceutical industry recognised temperature ranges, without the need for external intervention - are able to cover customers’ various needs. By using lightweight, environmentally friendly material, the technology enables efficiency and reusability. The Swiss-engineered hybrid features include shock-absorbent feet to mitigate any breakage during transport and has a double-door system to protect the packing against humidity. 

The partnership between SkyCell and JAL is a first step into a joint vision to determinedly, faithfully, and creatively increase the shipment quality of highly valuable and sensitive products.

Chiara Venuti, Business Development Director and Airline Partners, SkyCell, comments: “I see this partnership with JAL as a firm commitment from SkyCell to support the Japanese pharmaceutical market. We play a key role together in delivering life-saving medicine in the most safe, secure, and sustainable way to the patients in need. A great journey starts with small steps, and we look forward to working together with a common mission focused on ensuring patients get the life-saving medicines they need in a sustainable and secure way.”   

Hidehiko Umehara, Vice President, Business Promotion Department, JAL Cargo comments: “On the signing of a Master Lease Agreement, JAL and SkyCell will work in close cooperation and coordination to provide our customers with peace of mind when using SkyCell containers, which have a temperature excursion rate of less than 0.1% and are capable of maintaining the required temperature range at the highest levels, and do not need electric power.”





More top stories you might be interested in.....


Follow this site here.



Monday, 6 September 2021

SkyCell expands reach with All Nippon Airways partnership to support growing import needs in Japan


SkyCell, the manufacturer of innovative hybrid pharmaceutical containers, has partnered with All Nippon Airways (ANA), Japan's largest airline, to help support pharmaceutical customers shipping in and out of Japan in a safe, secure, and sustainable way. 

The partnership with SkyCell will also see the airline reach more of its sustainability goals. ANA expects there to be stronger demand for sustainability in the future, and can offer its customers more sustainable shipping options through SkyCell.

SkyCell currently has one service centre in Japan that will support the Japanese market with container availability in the country.

SkyCell will be supporting ANA with its dedicated pharmaceutical containers across different temperature ranges to cover customers’ various needs. SkyCell containers maintain internal temperature stability in external conditions from as low as -30°C to as high as +70°C. The complete temperature range includes the deep-frozen container that is able to maintain internal temperatures between -80°C and -60°C for extended periods of time. Thanks to the innovative technology of SkyCell, ANA will be able to utilise full aircraft capacity, mitigating the traditional capacity limitations caused by the use of dry ice by making energy transfer more efficient.

Tuesday, 10 August 2021

SkyCell launches annual sustainability report; commits to reach carbon neutral by 2040

According to the Journal of Cleaner Production, the pharmaceutical industry’s emission intensity is 55% higher than that of the automotive industry, signalling the desperate need for action 


SkyCell, the leading manufacturer of innovative pharma containers, is publicly announcing its sustainability and carbon neutrality goals and its progress towards them in its first annual Sustainability Report. The Swiss company, whose containers’ CO2 emissions are already about half the industry standard due to technological innovation and sustainability-focused product design, wants to lead the way to a more sustainable pharmaceutical supply chain and help counter the mounting climate crisis. Through its ambitious goals focused on climate, circularity, and cooperation, SkyCell commits to reaching fully carbon neutrality by 2040.  

Since its creation in 2012, SkyCell has held Environmental, Sustainability and Governance (ESG) at the core of its operations. As part of its commitment to the UN Sustainable Development Goals and the Paris Agreement, SkyCell is strengthening its efforts to reduce greenhouse gasses by setting itself ambitious goals. 
   
These include running solely on renewable energies by the end of 2021 and reducing direct emissions from SkyCell’s operations, and indirect ones related to the energy used for the company’s activities, by 50% by 2030. SkyCell’s ultimate goal is to achieve full carbon neutrality by 2040, with minimal use of carbon certificates.* To further help the company reach its ambitious goal, SkyCell is exploring technological innovation through various partnerships such as with Swiss start-up, Airborn Fuels, to produce jet fuel out of CO2 and renewable energy.

Thursday, 17 June 2021

SkyCell and Etihad Cargo - working together to transport temperature-controlled pharmaceuticals in a safe, secure, and sustainable way.



Photo Etihad Cargo


SkyCell is one of the global leaders in the field of manufacturing data-driven temperature-controlled containers for the pharmaceutical industry. Etihad Cargo is the cargo and logistics arm of the mammoth and award-winning Etihad Aviation Group.  So it, therefore, seems such a natural fir for the two companies to work in partnership to bring customers a wide range of solutions to transport their temperature-controlled pharmaceuticals in a safe, secure, and sustainable way. 

SkyCell’s highly innovative hybrid containers will allow Etihad Cargo to optimise its supply chains by using data to predict and control risk. More than three-quarters of a billion data-points are available on factors like temperature, location, and time, the SkyCell containers also enable a failure rate of less than 0.1 per cent, while reducing CO2 emissions by almost half. 

 Both companies are committed to implementing sustainable practices across the pharma supply chain through SkyCell’s innovative hybrid containers and optimisation solutions


Photo SkyCell
Tracked with IoT (‘Internet of Things’) sensors, hybrid containers monitor the temperature conditions inside and outside the containers to ensure the full efficacy of pharmaceuticals is maintained until they reach patients. In the process, SkyCell’s containers both reduce a shipment’s carbon footprint by up to 50 per cent due to their lightweight and efficient design. The containers are also capable of charging independently without the need of human intervention, and help reduce the amount of medical waste that ends up in landfill due to throw-away solutions and product loss caused by temperature excursions. 

 

Wednesday, 16 June 2021

Etihad Cargo and SkyCell sustainably transport life-saving pharmaceuticals

Photo Etihad Cargo


SkyCell is one of the global leaders in the field of manufacturing data-driven temperature-controlled containers for the pharmaceutical industry. Etihad Cargo is the cargo and logistics arm of the mammoth and award-winning Etihad Aviation Group.  So it, therefore, seems such a natural fir for the two companies to work in partnership to bring customers a wide range of solutions to transport their temperature-controlled pharmaceuticals in a safe, secure, and sustainable way. 

SkyCell’s highly innovative hybrid containers will allow Etihad Cargo to optimise its supply chains by using data to predict and control risk. More than three-quarters of a billion data-points are available on factors like temperature, location, and time, the SkyCell containers also enable a failure rate of less than 0.1 per cent, while reducing CO2 emissions by almost half. 

 Both companies are committed to implementing sustainable practices across the pharma supply chain through SkyCell’s innovative hybrid containers and optimisation solutions


Photo SkyCell
Tracked with IoT (‘Internet of Things’) sensors, hybrid containers monitor the temperature conditions inside and outside the containers to ensure the full efficacy of pharmaceuticals is maintained until they reach patients. In the process, SkyCell’s containers both reduce a shipment’s carbon footprint by up to 50 per cent due to their lightweight and efficient design. The containers are also capable of charging independently without the need of human intervention, and help reduce the amount of medical waste that ends up in landfill due to throw-away solutions and product loss caused by temperature excursions. 

 

Wednesday, 19 May 2021

LATAM Cargo Group partners with SkyCell to bring innovative hybrid container solutions to South American pharmaceutical market

SkyCell containers will be used to ship pharmaceuticals across key countries such as Chile, Brazil, and Argentina and help the South American airline expanding its pharma services.



SkyCell, the leading manufacturer of temperature-controlled containers, has partnered with LATAM Cargo Group to help ship pharmaceuticals to South America in a secure, safe, and sustainable way. This partnership comes at a crucial time for the pharmaceutical industry in South America, as the PHARMA volumes being transported by LATAM this year has more than doubled, compared to the same period in 2020. 


LATAM Cargo Group has the network and the expertise the pharmaceutical market requires for South America, and its use of SkyCell’s innovative container solutions through this partnership will help ensure these life-saving biologics make it to their destination in pristine condition. 



LATAM Cargo's partnership with SkyCell will help increase supply chain reliability and flexibility by ensuring cargo is kept at the optimal temperature throughout its journey, monitored by SkyCell's IoT and Lane Risk Assessment technology. 

Thursday, 13 May 2021

LOT Polish Airlines and SkyCell, sign an agreement that extending LOT Cargo’s capabilities in the transport of medicines and pharmaceutical products (PIL).

 
LOT Polish Airlines and SkyCell, a Swiss provider of hybrid containers, signed an agreement that extends LOT Cargo’s capabilities in the transport of medicines and pharmaceutical products (PIL). 


Thanks to advanced technology, SkyCell’s hybrid containers guarantee to maintain a constant transport temperature necessary for transporting demanding shipments even to  distant regions of the world.


The transport of pharmaceutical products requires the airlines to apply specialist solutions and meet demanding standards guaranteeing safety and the highest quality of provided services. Pharma and Life-Science is a critical sector of global cargo transport for LOT; therefore, the company is constantly increasing its competencies and improving its offer addressed to companies operating in this industry. 



In July 2020, LOT Cargo obtained the IATA CEIV Pharma certificate, which gave the Polish carrier a place in the prestigious group of 25 airlines with a documented and approved PIL QMS Quality Management System for pharmaceutical shipment management.

Thursday, 6 May 2021

SkyCell and DB Schenker sign new partnership deal



DB Schenker increases response to the pandemic by signing a Master Lease Agreement (MLA) with SkyCell. The partnership enables DB Schenker to enhance its vaccine logistics service solutions with additional flexibility through the new healthcare product DB SCHENKERlife+. Based in Switzerland, SkyCell manufactures innovative temperature-controlled air freight containers for pharmaceutical supply chains that can maintain internal temperatures as low as -80°C to -15°C for a minimum of five days, and temperatures of +2°C to +8°C and +15°C to +25°C for more than eight days. As part of the new partnership with SkyCell, DB Schenker’s service portfolio is extended by an additional reliable packaging solution to transport lifesaving pharmaceutical products, such as vaccines against Covid-19, globally. 

Milestone agreement for the lease of SkyCell’s hybrid pharma containers • Containers maintain constant temperatures for more than a week • Suitable for all Covid-19 vaccines on the market 



Thorsten Meincke, Global Board Member for Air & Ocean Freight at DB Schenker: “Logistics matters extensively in trying to overcome the pandemic and DB Schenker is already transporting Covid-19 vaccines worldwide. With this agreement, we upgrade our existing broad portfolio of healthcare-related logistics services with even more capability for our customers for the widespread roll-out of global vaccinations. With SkyCell, we have found an excellent partner in this endeavor to provide high quality on a global level.” 

Wednesday, 5 May 2021

DB Schenker signs partnership with SkyCell: Temperature-controlled containers for lifesaving medicine and Covid-19 vaccines

DB Schenker increases response to the pandemic by signing a Master Lease Agreement (MLA) with SkyCell. The partnership enables DB Schenker to enhance its vaccine logistics service solutions with additional flexibility through the new healthcare product DB SCHENKERlife+. Based in Switzerland, SkyCell manufactures innovative temperature-controlled air freight containers for pharmaceutical supply chains that can maintain internal temperatures as low as -80°C to -15°C for a minimum of five days, and temperatures of +2°C to +8°C and +15°C to +25°C for more than eight days. As part of the new partnership with SkyCell, DB Schenker’s service portfolio is extended by an additional reliable packaging solution to transport lifesaving pharmaceutical products, such as vaccines against Covid-19, globally. 

Milestone agreement for the lease of SkyCell’s hybrid pharma containers • Containers maintain constant temperatures for more than a week • Suitable for all Covid-19 vaccines on the market 



Thorsten Meincke, Global Board Member for Air & Ocean Freight at DB Schenker: “Logistics matters extensively in trying to overcome the pandemic and DB Schenker is already transporting Covid-19 vaccines worldwide. With this agreement, we upgrade our existing broad portfolio of healthcare-related logistics services with even more capability for our customers for the widespread roll-out of global vaccinations. With SkyCell, we have found an excellent partner in this endeavor to provide high quality on a global level.” 

Wednesday, 14 April 2021

Virgin Atlantic to ship vaccines through partnership with SkyCell

Virgin Atlantic’s Pharma service will use SkyCell’s temperature-controlled containers to ship valuable, life-saving pharmaceuticals


                                       SkyCell, one of the leading manufacturers of innovative pharma containers, has partnered with Virgin Atlantic to contribute to its safe, secure, and sustainable shipment of valuable vaccines and pharma products. Virgin Atlantic will use SkyCell containers covering the full range of biologics transit temperature requirements: -80°C, -25°C to -15°C, +2°C to +8°C, and up to +15°C to + 25°C.

The partnership will give customers confidence that their pharmaceutical shipments will arrive at destination safely, as the innovative hybrid containers - which have an average runtime of 202 hours - have a failure rate of less than 0.1%. This is compared to an industry standard failure rate of up to 12%, which cost the pharma industry $34.1 billion in 2019 alone.